TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02120027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
Study: NCT02701985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-placebo capsules will be administered orally, 2 times a day with food.
Study: NCT01002872
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of placebo will be 1 pill three times a day
Study: NCT03432923
Drug: Benzocaine 8 mg
Normalized name: benzocaine 8 MG
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
Study: NCT01259050
Drug: Zinc and Copper
Normalized name: copper gluconate / zinc picolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optizinc 90 mg/d Copper 1 mg
Study: NCT00640627
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule once daily for 6 weeks
Study: NCT00640627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo for 6 weeks
Study: NCT02332720
Drug: MK-3682B
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
Study: NCT04517864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, dosed as 4 tablets QD or 1 tablet QD
Study: NCT00444470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo.
Study: NCT03233243
Drug: Rosuvastatin Oral Tablet
Normalized name: rosuvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
Study: NCT01315093
Drug: Heparin, Low-Molecular-Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin from start till hcg test
Study: NCT01315093
Drug: no heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04487093
Drug: neoantigen vaccine + anti-angioge
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoantigen vaccine + anti-angioge
Study: NCT03105674
Drug: Multi-drug local anesthetics (Combination)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml
Study: NCT03105674
Drug: Standard local anesthetics (Combination)
Normalized name: local opthalmologic anesthetic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marcaine and Lidocaine
Study: NCT01034267
Drug: F2695 SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
Study: NCT02975570
Drug: WHO MDR-TB regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
Study: NCT03255824
Drug: Propofol, Midazolam, and Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
Study: NCT00677833
Drug: Azithromycin plus Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
Study: NCT04424862
Drug: Ponticelli Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
Study: NCT02037048
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02037048
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00678314
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml
Study: NCT01698684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose 15 minutes before attempting intercourse
Study: NCT02184611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
Study: NCT04493216
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
Study: NCT04493216
Drug: FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
Study: NCT04493216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK3640254 was administered in the form of tablets via oral route.
Study: NCT04700436
Drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
Study: NCT00770107
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
Study: NCT00770107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, for a duration of 4 weeks
Study: NCT04272580
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preload was given before spinal anesthesia.
Study: NCT04272580
Drug: 4 ml/kg group.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Study: NCT04272580
Drug: 8 ml/kg group.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Study: NCT04272580
Drug: 12 ml/kg group.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Study: NCT01792479
Drug: BIND-014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02798510
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01519531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
Study: NCT02623322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single dose by IV administration.
Study: NCT04466748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
Study: NCT03232983
Drug: LY900014 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01973660
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole or tamoxifen will be prescribed according to patient's menopausal status
Study: NCT01641393
Drug: EUR-1008 25,000 Units
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
Study: NCT01641393
Drug: Kreon 25,000 Units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
Study: NCT01687257
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF 400 mg tablet administered orally once daily
Study: NCT05343780
Drug: Heptex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukung Anak 200 mg + Milk thistle 100 mg
Study: NCT00180635
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml
Study: NCT01218126
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparison with active
Study: NCT02549469
Drug: Naproxen Sodium ER (BAY117031), 30% HPMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 660 mg administered orally once daily
Study: NCT02549469
Drug: Naproxen Sodium ER (BAY117031), 40% HPMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 660 mg administered orally once daily
Study: NCT00443937
Drug: enteric-coated mycophenolate sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT04681729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT02803268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01860703
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin-matching placebo
Study: NCT02678312
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
Study: NCT02678312
Drug: Placebo of LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02678312
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
Study: NCT00818961
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
Study: NCT00818961
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 administered on days +1, +3 and +6
Study: NCT00753792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
Study: NCT03136445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (saline) or oral placebo tablets
Study: NCT01918735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control matched to the oral or intravenous experimental comparator drug
Study: NCT01918735
Drug: GWP42006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects.
Study: NCT02137161
Drug: Dexamethasone+Tobramycin eye drop
Normalized name: dexamethasone / tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
Study: NCT02137161
Drug: Bromfenac eye drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromfenac ophthalmic solution 0.09%
Study: NCT01936025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04609033
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: instillation of local anaesthetic in the abdominal cavity at the end of the procedure
Study: NCT06069219
Drug: Epidural administration of sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
Study: NCT02306759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 50ml, administered over 15 minutes
Study: NCT02666547
Drug: 68Ga-NODAGA-RGD PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
Study: NCT02170740
Drug: BIBR 1048 MS - high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03503266
Drug: [14C] MT-7117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-C MT-7117
Study: NCT01831622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
Study: NCT02215122
Drug: MGR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study: NCT02215122
Drug: Advair® Diskus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study: NCT02215122
Drug: Seretide™ Accuhaler™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study: NCT04881006
Drug: Farxiga® 10 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured by AstraZeneca Pharmaceuticals LP
Study: NCT00686881
Drug: Comparator: Stronger neo minophagen C (SNMC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
Study: NCT02616874
Drug: MVA.HIVconsv vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
Study: NCT00003500
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01951638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00030030
Drug: Silymarin (milk thistle)
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02660866
Drug: Placebo + background APT + SMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study: NCT06733506
Drug: Isopropyl Alcohol 70% Topical Application Solution
Normalized name: Isopropyl Alcohol 70% Topical application Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
Study: NCT02173548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04657744
Drug: Sphingomod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule contains 0.5 mg Fingolimod
Study: NCT00549757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match aliskiren 150 mg film-coated tablets
Study: NCT04984707
Drug: KX0826
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR antagonist
Study: NCT00258258
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02591238
Drug: non-smoker oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Study: NCT02591238
Drug: smoker oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Study: NCT02899325
Drug: Diagnostic PET/CT scans
Approvals — FDA: no, EMA: no, PMDA: no
Description: These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
Study: NCT00002611
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002611
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
Study: NCT03813238
Drug: TEV-50717
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage ranging from 6 mg to 48 mg.
Study: NCT03813238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage ranging from 6 mg to 48 mg.
Study: NCT02398929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be given once daily for 2 weeks during the run-in period.
Study: NCT01494987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ranolazine for the duration of the study
Study: NCT01335867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills
Study: NCT02565914
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose tablet for oral administration.
Study: NCT03080805
Drug: Pyrotinib Plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
Study: NCT03080805
Drug: Lapatinib Plus Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
Study: NCT02031198
Drug: AADvac1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunization against pathological Alzheimer's disease tau protein
Study: NCT02642250
Drug: Entoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
Study: NCT04525495
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine treatment
Study: NCT00644631
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
Study: NCT02905825
Drug: BreathID® Hp Lab System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Study: NCT01578811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage
Study: NCT01009918
Drug: Coreg CR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03546894
Drug: Any FDA Approved ALK Inhibitors
Normalized name: Anaplastic lymphoma kinase (ALK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved ALK inhibitors available for treatment.
Study: NCT01094925
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02972957
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
Study: NCT01588626
Drug: AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01934933
Drug: Enbrel plus Celebrex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246127
Drug: STZ-5FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT00028106
Drug: [131]I-MIBG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00028106
Drug: 6-[18F]Fluorodopamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00028106
Drug: [123]I-MIBG
Approvals — FDA: no, EMA: no, PMDA: no